Exploring the specificity of the PI3K family inhibitor LY294002

Biochemical Journal

Volumn 404, Issue 1, 2007, Pages 15-21

  Gharbi, Severine I ^a   Zvelebil, Marketa J ^a   Shuhleworth, Stephen J ^b   Hancox, Tim ^b   Saghir, Nahid ^b   Timms, John F ^a,c   Waterfield, Michael D ^a,b  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^b Plramed Ltd   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Brd4; Chemical proteomic strategy; LY294002; Phosphatidylinositol 3 kinase (PI3k); Valosin containing protein (VCP)

Indexed keywords

CELL GROWTH; CELL PROLIFERATION; ELECTROPHORESIS; LIPIDS; LIQUID CHROMATOGRAPHY; METABOLISM; PHYSIOLOGY; PROTEINS; TUMORS;

GEL ELECTROPHORESIS; INFLAMMATION; LIPID KINASES; VALOSIN CONTAINING PROTEIN (VCP);

ENZYME KINETICS;

2 MORPHOLINO 8 PHENYLCHROMONE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; WORTMANNIN;

ARTICLE; CELL DIFFERENTIATION; CELL GROWTH; CELL METABOLISM; CELL PROLIFERATION; CONTROLLED STUDY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEOMICS;

ANIMALS; CELL LINE; CELL SURVIVAL; CELLS, CULTURED; CHROMONES; CULTURE MEDIA; ENZYME INHIBITORS; HUMANS; KINETICS; MODELS, ANIMAL; MORPHOLINES; PROTEINS; SIGNAL TRANSDUCTION;

EID: 34247339936     PISSN: 02646021     EISSN: None     Source Type: Journal    
DOI: 10.1042/BJ20061489     Document Type: Article

References (54)

1. Engelman, J. A., Luo, J. and Cantley, L. C. (2006) The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 7, 606-619
2. Carpenter, C. L. and Cantley, L. C. (1996) Phosphoinositide kinases. Curr. Opin. Cell Biol. 8, 153-158
3. Vanhaesebroeck, B. and Waterfield, M. D. (1999) Signaling by distinct classes of phosphoinositide 3-kinases. Exp. Cell Res. 253, 239-254
4. Pawson, T. and Nash, P. (2003) Assembly of cell regulatory systems through protein interaction domains. Science 300, 445-452
5. Rameh, L. E. and Cantley, L. C. (1999) The role of phosphoinositide 3-kinase lipid products in cell function. J. Biol. Chem. 274, 8347-6350
6. Drees, B. E. M. G. B., Rommel, C. and Prestwich, G. D. (2004) Therapeutic potential of phosphoinositide 3-kinase inhibitors. Expert Opin. Ther. Patents 14, 703-732
7. Rogers, S. J., Box, C., Harrington, K. J., Nutting, C., Rhys-Evans, P. and Eccles, S. A. (2005) The phosphoinositide 3-kinase signalling pathway as a therapeutic target in squamous cell carcinoma of the head and neck. Expert. Opin. Ther. Targets 9, 769-790
8. Kang, S., Bader, A. G. and Vogt, P. K. (2005) Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc. Natl. Acad. Sci. U.S.A. 102, 802-807
9. Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J. et al. (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554
10. Cully, M., You, H., Levine, A. J. and Mak, T. W. (2006) Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev. Cancer 6, 184-192
11. Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y. and Mills, G. B. (2005) Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 4, 988-1004
12. Stephens, L., Williams, R. and Hawkins, P. (2005) Phosphoinositide 3-kinases as drug targets in cancer. Curr. Opin. Pharmacol. 5, 357-365
13. Brachmann, S. M., Yballe, C. M., Innocenti, M., Deane, J. A., Fruman, D. A., Thomas, S. M. and Cantley, L. C. (2005) Role of phosphoinositide 3-kinase regulatory isoforms in development and actin rearrangement. Mol. Cell Biol. 25, 2593-2606
14. Okkenhaug, K., Bilancio, A., Farjot, G., Priddle, H., Sancho, S., Peskett, E., Pearce, W., Meek, S. E., Salpekar, A. and Waterfield, M. D. et al. (2002) Impaired B and T cell antigen receptor signaling in p110δ PI3-kinase mutant mice. Science 297, 1031-1034
15. Foukas, L. C., Claret, M., Pearce, W., Okkenhaug, K., Meek, S., Peskett, E., Sancho, S., Smith, A. J., Withers, D. J. and Vanhaesebroeck, B. (2006) Critical role for the p110α phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 441, 366-370
16. Arcaro, A. and Wymann, M. P. (1993) Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses. Biochem. J. 296, 297-301
17. Yano, H., Nakanishi, S., Kimura, K., Hanai, N., Saitoh, Y., Fukui, Y., Nonomura, Y. and Matsuda, Y. (1993) Inhibition of histamine secretion by wortmannin through the blockade of phosphatidylinositol 3-kinase in RBL-2H3 cells. J. Biol. Chem. 268, 25846-25856
18. Vlahos, C. J., Matter, W. F., Hui, K. Y. and Brown, R. F. (1994) A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl- 4H-1-benzopyran-4-one (LY294002). J. Biol. Chem. 269, 5241-5248
19. Brunn, G. J., Williams, J., Sabers, C., Wiederrecht, G., Lawrence, Jr, J. C. and Abraham, R. T. (1996) Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J. 15, 5256-5267
20. Davies, S. P., Reddy, H., Caivano, M. and Cohen, P. (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351, 95-105
21. Jacobs, M. D., Black, J., Futer, O., Swenson, L., Hare, B., Fleming, M. and Saxena, K. (2005) PIM-1 ligand-bound structures reveal the mechanism of serine/threonine kinase inhibition by LY294002. J. Biol. Chem. 280, 13728-13734
22. Abdul-Ghani, R., Serra, V., Gyorffy, B., Jurchott, K., Solf, A., Dietel, M. and Schafer, R. (2006) The PI3K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1. Oncogene 25, 1743-1752
23. Choi, E. K., Park, H. J., Ma, J. S., Lee, H. C., Kang, H. C., Kim, B. G. and Kang, I. C. (2004) LY294002 inhibits monocyte chemoattractant protein-1 expression through a phosphatidylinositol 3-kinase-independent mechanism. FEBS Lett. 559, 141-144
24. Kim, Y. H., Choi, K. H., Park, J. W. and Kwon, T. K. (2005) LY294002 inhibits LPS-induced NO production through a inhibition of NF-κB activation: independent mechanism of phosphatidylinositol 3-kinase. Immunol. Lett. 99, 45-50
25. Poh, T. W. and Pervaiz, S. (2005) LY294002 and LY303511 sensitize tumor cells to drug-induced apoptosis via intracellular hydrogen peroxide production independent of the phosphoinositide 3-kinase-Akt pathway. Cancer Res. 65, 6264-6274
26. Yamaguchi, K., Lee, S. H., Kim, J. S., Wimalasena, J., Kitajima, S. and Baek, S. J. (2006) Activating transcription factor 3 and early growth response 1 are the novel targets of LY294002 in a phosphatidylinositol 3-kinase-independent pathway. Cancer Res. 66, 2376-2384
27. Tolloczko, B., Turkewitsch, P., Al Chalabi, M. and Martin, J. G. (2004) LY-294002 [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] affects calcium signaling in airway smooth muscle cells independently of phosphoinositide 3-kinase inhibition. J. Pharmacol. Exp. Ther. 311, 787-793
28. Godi, K., Wissing, J., Kurtenbach, A., Habenberger, P., Blencke, S., Gutbrod, H., Salassidis, K., Stein-Gerlach, M., Missio, A., Cotten, M. and Daub, H. (2003) An efficient proteomics method to identify the cellular targets of protein kinase inhibitors. Proc. Natl. Acad. Sci. U.S.A. 100, 15434-15439
29. Knockaert, M., Wieking, K., Schmitt, S., Leost, M., Grant, K. M., Mottram, J. C., Kunick, C. and Meijer, L. (2002) Intracellular targets of paullones: identification following affinity purification on immobilized inhibitor. J. Biol. Chem. 277, 25493-25501
30. Abbott, B. and Thompson, P. (2003) Synthetic studies of the phosphatidylinositol 3-kinase inhibitor LY294002 and related analogues. Aust. J. Chem. 56, 1099-1106
31. Abbott, B. M. and Thompson, P. E. (2004) PDE2 inhibition by the PI3 kinase inhibitor LY294002 and analogues. Bioorg. Med. Chem. Lett. 14, 2847-2851
32. Gharbi, S., Gatfney, P., Yang, A., Zvelebil, M. J., Cramer, R., Waterfield, M. D. and Timms, J. F. (2002) Evaluation of two-dimensional differential gel electrophoresis for proteomic expression analysis of a model breast cancer cell system. Mol. Cell Proteomics 1, 91-98
33. Ye, Y., Meyer, H. H. and Rapoport, T. A. (2003) Function of the p97-Ufd1-Npl4 complex in retrotranslocation from the ER to the cytosol: dual recognition of nonubiquitinated polypeptide segments and polyubiquitin chains. J. Cell Biol. 162, 71-84
34. Meyer, H. H., Shorter, J. G., Seemann, J., Pappin, D. and Warren, G. (2000) A complex of mammalian ufd1 and npl4 links the AAA-ATPase, p97, to ubiquitin and nuclear transport pathways. EMBO J. 19, 2181-2192
35. Walker, E. H., Pacold, M. E., Perisic, O., Stephens, L., Hawkins, P. T., Wymann, M. P. and Williams, R. L. (2000) Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol. Cell 6, 909-919
36. Walker, E. H., Perisic, O., Ried, C., Stephens, L. and Williams, R. L. (1999) Structural insights into phosphoinositide 3-kinase catalysis and signalling. Nature 402, 313-320
37. Pirola, L., Zvelebil, M. J., Bulgarelli-Leva, G., Van Obberghen, E., Waterfield, M. D. and Wymann, M. P. (2001) Activation loop sequences confer substrate specificity to phosphoinositide 3-kinase α (PI3Kα): functions of lipid kinase-deficient PI3Kα in signaling. J. Biol. Chem. 276, 21544-21554
38. Bilancio, A., Okkenhaug, K., Camps, M., Emery, J. L., Ruckle, T., Rommel, C. and Vanhaesebroeck, B. (2006) Key role of the p110aδ isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110δ function in B cells. Blood 107, 642-650
39. Kihara, A., Kabeya, Y., Ohsumi, Y. and Yoshimori, T. (2001) Beclin-phosphatidylinositol 3-kinase complex functions at the trans-Golgi network. EMBO Rep. 2, 330-335
40. Downing, G. J., Kim, S., Nakanishi, S., Catt, K. J. and Balla, T. (1996) Characterization of a soluble adrenal phosphatidylinositol 4-kinase reveals wortmannin sensitivity of type III phosphatidylinositol kinases. Biochemistry 35, 3587-3594
41. Meyers, R. and Cantley, L. C. (1997) Cloning and characterization of a wortmannin-sensitive human phosphatidylinositol 4-kinase. J. Biol. Chem. 272, 4384-4390
42. Fan, Q. W., Knight, Z. A., Goldenberg, D. D., Yu, W., Mostov, K. E., Stokoe, D., Shokat, K. M. and Weiss, W. A. (2006) A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9, 341-349
43. Knight, Z. A., Gonzalez, B., Feldman, M. E., Zunder, E. R., Goldenberg, D. D., Williams, O., Loewith, R., Stokoe, D., Balla, A., Toth, B. et al. (2006) A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling. Cell 125, 733-747
44. Ding, J., Vlahos, C. J., Liu, R., Brown, R. F. and Badwey, J. A. (1995) Antagonists of phosphatidylinositol 3-kinase block activation of several novel protein kinases in neutrophils. J. Biol. Chem. 270, 11684-11691
45. Landesman-Bollag, E., Romieu-Mourez, R., Song, D. H., Sonenshein, G. E., Cardiff, R. D. and Seldin, D. C. (2001) Protein kinase CK2 in mammary gland tumorigenesis. Oncogene 20, 3247-3257
46. Doble, B. W. and Woodgett, J. R. (2003) GSK-3: tricks of the trade for a multi-tasking kinase. J. Cell Sci. 116, 1175-1186
47. Cross, D. A., Alessi, D. R., Cohen, P., Andjelkovich, M. and Hemmings, B. A. (1995) Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378, 785-789
48. Abbott, B. M. and Thompson, P. E. (2004) PDE2 inhibition by the PI3 kinase inhibitor LY294002 and analogues. Bioorg. Med. Chem. Lett. 14, 2847-2851
49. Halawani, D. and Latterich, M. (2006) p97: The cell's molecular purgatory? Mol. Cell 22, 713-717
50. Kang, J. H., Hong, M. L., Kim, D. W., Park, J., Kang, T. C., Won, M. H., Baek, N. I., Moon, B. J., Choi, S. Y. and Kwon, O. S. (2004) Genomic organization, tissue distribution and deletion mutation of human pyridoxine 5′-phosphate oxidase. Eur. J. Biochem. 271, 2452-2461
51. Bach, S., Knockaert, M., Reinhardt, J., Lozach, O., Schmitt, S., Baratte, B., Koken, M., Coburn, S. P., Tang, L., Jiang, T. et al. (2005) Roscovitine targets, protein kinases and pyridoxal kinase. J. Biol. Chem. 280, 31208-31219
52. Dey, A., Chitsaz, F., Abbasi, A., Misteli, T. and Ozato, K. (2003) The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis. Proc. Natl. Acad. Sci. U.S.A. 100, 8758-8763
53. Farina, A., Hattori, M., Qin, J., Nakatani, Y., Minato, N. and Ozato, K. (2004) Bromodomain protein Brd4 binds to GTPase-activating SPA-1, modulating its activity and subcellular localization. Mol. Cell Biol. 24, 9059-9069
54. Sinha, A., Faller, D. V. and Denis, G. V. (2005) Bromodomain analysis of Brd2-dependent transcriptional activation of cyclin A1. Biochem. J. 387, 257-269